IMS Health Holdings Inc (IMS) was Downgraded by Wells Fargo to ” Market Perform”. Earlier the firm had a rating of “Outperform ” on the company shares. Wells Fargo advised their investors in a research report released on May 12, 2016.
Many Wall Street Analysts have commented on IMS Health Holdings Inc. Company shares were Reiterated by Topeka Capital Markets on May 4, 2016 to “Buy”, Firm has raised the Price Target to $ 30 from a previous price target of $29 .Leerink Partners Resumed IMS Health Holdings Inc on Feb 24, 2016 to “Outperform”, Price Target of the shares are set at $31.
On the company’s financial health, IMS Health Holdings Inc reported $0.42 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.38. The company had revenue of $774.00 million for the quarter, compared to analysts expectations of $749.54 million. The company’s revenue was up 22.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.39 EPS.
IMS Health Holdings Inc opened for trading at $25.32 and hit $25.58 on the upside on Tuesday, eventually ending the session at $25.57, with a gain of 0.79% or 0.2 points. The heightened volatility saw the trading volume jump to 15,95,381 shares. Company has a market cap of $8,435 M.
In a different news, on Nov 25, 2015, Kevin C Knightly (SVP, Information Offerings) sold 19,231 shares at $28.50 per share price. According to the SEC, on Aug 6, 2015, John G Danhakl (director) sold 2,166,065 shares at $31.17 per share price.
IMS Health Holdings Inc. (IMS) is an information and technology services company that provides solutions to its clients in the healthcare industry. The Company has its presence in over 100 countries. The Companys data set contains over 10 petabytes of data and over 500 million patient records. The Company serves healthcare organizations and life science companies including pharmaceutical biotechnology consumer health and medical device manufacturers as well as distributors providers payers government agencies policymakers researchers and the financial community. The Companys principal offerings include national information offerings sub-national information offerings workflow analytics real-world evidence (RWE) solutions technology and applications and clinical solutions.